How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,808 results for

Osteosarcoma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Effectiveness of <sup>18</sup>F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies. (PubMed)

Effectiveness of 18F-FDG PET/CT in the diagnosis and staging of osteosarcoma: a meta-analysis of 26 studies. Multiple trials have attempted to assess the diagnostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in osteosarcoma with results remaining inconclusive. This study aims to investigate the effectiveness of 18F-FDG PET and PET/CT in the diagnosis, staging, recurrence and metastasis formation observations of osteosarcoma (...) through systematic review followed by meta-analysis.Three electronic databases, Medline/PubMed, Embase and the Cochrane Library were utilized in this study. Eligible studies that assessed the performance of 18F-FDG PET/CT for the diagnosis, staging, restaging and recurrence monitoring of osteosarcoma were retrieved utilizing specific search criteria. After screening and diluting out the non-conforming articles, all relevant articles and their data were identified and extracted to calculate the summary

Full Text available with Trip Pro

2019 BMC Cancer

62. Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®): Health Professional Version

Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®): Health Professional Version Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf Warning: The NCBI web site requires JavaScript to function. Search database Search term Search NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer (...) Institute (US); 2002-. PDQ Cancer Information Summaries [Internet]. Bethesda (MD): ; 2002-. Search term Osteosarcoma and Malignant Fibrous Histiocytoma of Bone Treatment (PDQ®) Health Professional Version PDQ Pediatric Treatment Editorial Board . Published online: January 30, 2019. This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of osteosarcoma and malignant fibrous histiocytoma of bone. It is intended

2017 PDQ - NCI's Comprehensive Cancer Database

63. Gnathic Osteosarcoma: Clinical, Radiologic, and Pathologic Review of Bone Beard Tumor (PubMed)

Gnathic Osteosarcoma: Clinical, Radiologic, and Pathologic Review of Bone Beard Tumor 29244987 2019 01 14 2019 01 14 2378-9506 3 6 2017 12 Journal of global oncology J Glob Oncol Gnathic Osteosarcoma: Clinical, Radiologic, and Pathologic Review of Bone Beard Tumor. 823-827 10.1200/JGO.2016.006494 Mahajan Abhishek A All authors: Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra, India. Vaish Richa R All authors: Tata Memorial Hospital, Tata Memorial Centre, Mumbai, Maharashtra (...) 101674751 2378-9506 IM Breast Neoplasms diagnosis pathology surgery Carcinoma, Ductal, Breast diagnosis pathology surgery Female Humans Jaw Neoplasms diagnosis surgery Magnetic Resonance Imaging Middle Aged Osteosarcoma diagnosis surgery Tomography, X-Ray Computed 2017 12 16 6 0 2017 12 16 6 0 2019 1 15 6 0 ppublish 29244987 10.1200/JGO.2016.006494 PMC5735964 J Clin Oncol. 1997 Jan;15(1):363-7 8996163 J Oral Maxillofac Surg. 2011 Sep;69(9):2368-75 21288615 Med Oncol. 2014 Sep;31(9):171 25134917 Head

Full Text available with Trip Pro

2016 Journal of global oncology

64. Review of Osteosarcoma and Current Management (PubMed)

Review of Osteosarcoma and Current Management Osteosarcoma is the most common primary malignancy of bone in children and young adults. This tumor has a very heterogeneous genetic profile and lacks any consistent unifying event that leads to the pathogenesis of osteosarcoma. In this review, some of the important genetic events involved in osteosarcoma will be highlighted. Additionally, the clinical diagnosis of osteosarcoma will be discussed, as well as contemporary chemotherapeutic and surgical

Full Text available with Trip Pro

2016 Rheumatology and therapy

65. Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. (PubMed)

Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. Radiation therapy has been long utilized as localized cancer treatment. Recent studies have also demonstrated that it has a distant effect by the enhanced immunity, but it rarely occurs. The purpose of this study was to investigate whether X-ray irradiation combined with anti-PD-L1 and anti-CTLA-4 antibodies (P1C4) provides a higher probability of this distant effect as well (...) as enhanced local antitumor efficacy for osteosarcoma. LM8 mouse osteosarcoma cells were inoculated into both legs of C3H mice assigned to one of four groups, namely no treatment (No Tx), P1C4, X-ray irradiation (RAD) to the leg of one side, and combination (COMB) groups. Survival and treatment-related immune molecular changes were analyzed. Administration of P1C4 produced a tumor growth delay on day 30 in 18% of the mice. In contrast, combination therapy produced the strongest tumor growth inhibition

Full Text available with Trip Pro

2017 PLoS ONE

66. Patient-derived osteosarcoma cells are resistant to methotrexate. (PubMed)

Patient-derived osteosarcoma cells are resistant to methotrexate. Osteosarcoma is the most common primary bone tumor in children and young adults. The median survival of osteosarcoma patients has not significantly improved since 1990, despite administration of different classes of chemotherapy agents, such as methotrexate, cisplatin and doxorubicin. Cancer stem cells (CSCs) are responsible for the resistance of osteosarcoma to chemotherapy and OCT4, SOX2 and SSEA4 have been used to identify (...) CSCs in osteosarcoma. Here, we used low-passage patient-derived osteosarcoma cells and osteosarcoma cells directly isolated from patients before and after chemotherapy treatments to evaluate the effects of chemotherapy on stem cell markers expression. We demonstrate that primary osteosarcoma cells are resistant to methotrexate treatment and sensitive to cisplatin and doxorubicin in vitro. We also verified that cisplatin and doxorubicin reduce the expression of SOX2 and OCT4 in primary osteosarcoma

Full Text available with Trip Pro

2017 PLoS ONE

67. The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells. (PubMed)

The dynamic role of autophagy and MAPK signaling in determining cell fate under cisplatin stress in osteosarcoma cells. Osteosarcoma (OS) is an aggressive bone malignancy commonly observed in children and adolescents. Sub-optimal therapy for years has irretrievably compromised the chances of OS patient survival; also, lack of extensive research on this rare disease has hindered therapeutic development. Cisplatin, a common anti-tumor drug, is currently an integral part of treatment regime for OS (...) alterations that can be considered for development of improved therapeutic strategy against osteosarcoma.

Full Text available with Trip Pro

2017 PLoS ONE

68. MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7. (PubMed)

MicroRNA-448 suppresses osteosarcoma cell proliferation and invasion through targeting EPHA7. Osteosarcoma is the most common type of malignant bone tumor, often affecting adolescents and children. MicroRNAs (miRNAs) are a group of small, non-protein coding, endogenous RNAs that play critical roles in osteosarcoma tumorigenesis. In our study, we demonstrated that miR-448 expression was downregulated in osteosarcoma tissues and cell lines. Overexpression of miR-448 suppressed osteosarcoma cell (...) proliferation, colony formation and migration. Moreover, we found that EPHA7 was a direct target gene of miR-448 in osteosarcoma cells. We further demonstrated that the EPHA7 expression level was upregulated in osteosarcoma tissues. Interestingly, the expression level of EPHA7 was inversely correlated with the expression level of miR-448 in osteosarcoma tissues. In addition, elevated expression of miR-448 suppressed osteosarcoma cell proliferation and invasion through targeting EPHA7. Taken together

Full Text available with Trip Pro

2017 PLoS ONE

69. Prognostic significance of chemotherapy-induced necrosis in osteosarcoma patients receiving pasteurized autografts. (PubMed)

Prognostic significance of chemotherapy-induced necrosis in osteosarcoma patients receiving pasteurized autografts. Among various reconstruction methods after wide excision for osteosarcoma, pasteurized autograft is often preferred. While the whole area of the tumor can be assessed for chemotherapy-induced necrosis, one of the important prognostic factors, in other reconstructive techniques, only a portion removed from a wide-resection specimen is available when using pasteurized autograft (...) method. The assessment, therefore, may be unreliable. We analyzed the prognostic significance of the chemotherapy-induced necrosis in osteosarcoma patients who underwent reconstruction with pasteurized autografts.We reviewed the records of osteosarcoma patients who underwent treatment in our institution from 1998 to 2013. Cases of reconstruction with pasteurized autografts were defined as the patient group, and the same number of patients who underwent other reconstruction methods served as controls

Full Text available with Trip Pro

2017 PLoS ONE

70. Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis. (PubMed)

Lack of association between platelet indices and disease stage in osteosarcoma at diagnosis. The purpose of this study was to investigate the relationship between platelet indices [mean platelet volume (MPV), platelet count (PLT), platelet distribution width (PDW) and plateletcrit (PCT)] at diagnosis in osteosarcoma.The information of 233 patients with osteosarcoma at diagnosis between 2007 and 2015 was retrospectively reviewed. Clinical parameters such as gender, age, size and site of tumor (...) platelet indices were noted among the different stages. Although a shorter median DFS was found in localized patients with PLT≥300×109/L, there was still a lack of strong evidence to demonstrate the association between platelet indices and osteosarcoma.

Full Text available with Trip Pro

2017 PLoS ONE

71. The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. (PubMed)

The effect of bone morphogenetic protein-2 on osteosarcoma metastasis. Bone Morphogenetic Protein-2 (BMP-2) may offer the potential to enhance allograft-host osseous union in limb-salvage surgery following osteosarcoma resection. However, there is concern regarding the effect of locally applied BMP-2 on tumor recurrence and metastasis. The purpose of this project was to evaluate the effect of exogenous BMP-2 on osteosarcoma migration and invasion across a panel of tumor cell lines in vitro (...) and to characterize the effect of BMP-2 on pulmonary osteosarcoma metastasis within a xenograft model.The effect of BMP-2 on in vitro tumor growth and development was assessed across multiple standard and patient-derived xenograft osteosarcoma cell lines. Tumor migration capacity, invasion, and cell proliferation were characterized. In addition, the effect on metastasis was measured using a xenograft model following tail-vein injection. The effect of exogenous BMP-2 on the development of metastases was measured

Full Text available with Trip Pro

2017 PLoS ONE

72. Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole. (PubMed)

Osteosarcoma cell proliferation and survival requires mGluR5 receptor activity and is blocked by Riluzole. Osteosarcomas are malignant tumors of bone, most commonly seen in children and adolescents. Despite advances in modern medicine, the poor survival rate of metastatic osteosarcoma has not improved in two decades. In the present study we have investigated the effect of Riluzole on a human and mouse metastatic osteosarcoma cells. We show that LM7 cells secrete glutamate in the media (...) and that mGluR5 receptors are required for the proliferation of LM7 cells. Riluzole, which is known to inhibit glutamate release, inhibits proliferation, induces apoptosis and prevents migration of LM7 cells. This is also seen with Fenobam, a specific blocker of mGluR5. We also show that Riluzole alters the phosphorylation status of AKT/P70 S6 kinase, ERK1/2 and JNK1/2. Thus Riluzole is an effective drug to inhibit proliferation and survival of osteosarcoma cells and has therapeutic potential

Full Text available with Trip Pro

2017 PLoS ONE

73. Synergistic Action of Genistein and Calcitriol in Immature Osteosarcoma MG-63 Cells by SGPL1 Up-Regulation. (PubMed)

Synergistic Action of Genistein and Calcitriol in Immature Osteosarcoma MG-63 Cells by SGPL1 Up-Regulation. Phytoestrogens such as genistein, the most prominent isoflavone from soy, show concentration-dependent anti-estrogenic or estrogenic effects. High genistein concentrations (>10 μM) also promote proliferation of bone cancer cells in vitro. On the other hand, the most active component of the vitamin D family, calcitriol, has been shown to be tumor protective in vitro and in vivo (...) . The purpose of this study was to examine a putative synergism of genistein and calcitriol in two osteosarcoma cell lines MG-63 (early osteoblast), Saos-2 (mature osteoblast) and primary osteoblasts.Thus, an initial screening based on cell cycle phase alterations, estrogen (ER) and vitamin D receptor (VDR) expression, live cell metabolic monitoring, and metabolomics were performed.Exposure to the combination of 100 μM genistein and 10 nM calcitriol reduced the number of proliferative cells to control

Full Text available with Trip Pro

2017 PLoS ONE

74. Osteosarcoma Overview (PubMed)

Osteosarcoma Overview Osteosarcoma (OS) is the most common primary malignancy of bone and patients with metastatic disease or recurrences continue to have very poor outcomes. Unfortunately, little prognostic improvement has been generated from the last 20 years of research and a new perspective is warranted. OS is extremely heterogeneous in both its origins and manifestations. Although multiple associations have been made between the development of osteosarcoma and race, gender, age, various

Full Text available with Trip Pro

2016 Rheumatology and therapy

75. Comprehensive Treatment and Rehabilitation of Patients With Osteosarcoma of the Mandible. (PubMed)

Comprehensive Treatment and Rehabilitation of Patients With Osteosarcoma of the Mandible. The article studies state-of-the art physical therapeutic techniques as a high degree of relevance to minimize invalidation and improve quality of life for patients with dental osteosarcoma.A randomized controlled clinical trial was conducted in 21 patients with osteogenic sarcoma of mandible (C41.1). There were 10 patients in the experimental group and 11 patients in the control group.A comprehensive (...) treatment and rehabilitation program for patients with osteosarcoma of mandible was developed. The first part of the program comprised 3 basic phases: preop chemotherapy, surgery, and postop rehabilitation. The surgical treatment further included resection of an affected part of the mandible and primary repair of the defect with jaw fragments and an autoimplant joined together with the help of positioning devices. The postop rehabilitation included postop chemotherapy and mesodiencephalic modulation

2018 Implant dentistry

76. The Curcumin Analog CH-5 Exerts Anticancer Effects in Human Osteosarcoma Cells via Modulation of Transcription Factors p53/Sp1 (PubMed)

The Curcumin Analog CH-5 Exerts Anticancer Effects in Human Osteosarcoma Cells via Modulation of Transcription Factors p53/Sp1 Curcumin is a potential anticancer drug with poor bioavailability, which limits its clinical use as a therapeutic agent. The aim of this study was a preliminary evaluation of the curcumin analogue CH-5 as a cytotoxic agent in human osteosarcoma cell lines U2OS, MG-63, and Saos-2. CH-5 inhibited cell viability at lower concentrations than curcumin, leading

Full Text available with Trip Pro

2018 International journal of molecular sciences

77. MicroRNA-2682-3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88 (PubMed)

MicroRNA-2682-3p inhibits osteosarcoma cell proliferation by targeting CCND2, MMP8 and Myd88 Osteosarcoma is the most common primary bone malignancy in children and young adults. It is associated with dysregulation of certain microRNAs (miRNAs/miRs), which provides a target for osteosarcoma therapy. miR-2682-3p expression in osteosarcoma cell lines and tissues was assayed by reverse transcription-quantitative polymerase chain reaction and was upregulated or downregulated by transfection (...) with miRNA mimics or inhibitors. miR-2682-3p was downregulated in osteosarcoma tissues and cell lines, and overexpression of miR-2682-3p inhibited tumor growth. Further studies revealed that cyclin D1 (CCND)2, matrix metalloproteinase (MMP)8, and myeloid differentiation primary response (Myd)88 were the direct targets of miR-2682-3p in osteosarcoma cells. Overexpression of miR-2682-3p promoted osteosarcoma cell apoptosis by targeting CCND2, MMP8, and Myd88, and vice-versa. Therefore, miR-2682-3p may act

Full Text available with Trip Pro

2018 Oncology letters

78. miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2 (PubMed)

miR-18a-5p promotes cell invasion and migration of osteosarcoma by directly targeting IRF2 An increasing number of studies have suggested that microRNAs (miRNAs) are involved in the progress of many human cancers including osteosarcoma (OS). Especially, microRNA-18a-5p (miR-18a-5p) has been reported to associate with the occurrence, development and clinical outcomes of human cancers. Therefore, we investigated the functions of miR-18a-5p in OS. Reverse transcription-quantitative PCR (RT-qPCR

Full Text available with Trip Pro

2018 Oncology letters

79. Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance (PubMed)

Codelivery of doxorubicin and JIP1 siRNA with novel EphA2-targeted PEGylated cationic nanoliposomes to overcome osteosarcoma multidrug resistance Osteosarcoma (OS) mostly affects children and young adults, and has only a 20%-30% 5-year survival rate when metastasized. We aimed to create dual-targeted (extracellular against EphA2 and intracellular against JNK-interacting protein 1 [JIP1]), doxorubicin (DOX)-loaded liposomes to treat OS metastatic disease.Cationic liposomes contained N-[1-(2,3

Full Text available with Trip Pro

2018 International journal of nanomedicine

80. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma (PubMed)

TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma In the past decades, chemotherapy has resulted in improved outcomes for patients with osteosarcoma. However, resistance to chemotherapy often leads to poor prognoses. Cisplatin is a standard drug for osteosarcoma therapy, and chemoresistance to cisplatin in osteosarcoma limits the effectiveness of chemotherapy drugs. Transglutaminase 2 (TGM2) is a member of the transglutaminase family, and it is reported to be associated (...) with chemoresistance in various types of cancer. The present study aimed to investigate the function of TGM2 in regulating chemosensitivity of osteosarcoma cells to cisplatin. For in vitro experiments, a cisplatin‑resistant osteosarcoma cell line (Saos2‑CIS‑R) was established, and TGM2 was demonstrated to be upregulated in the resistant Saos2‑CIS‑R cells compared with the normal Saos2 cells. The present study also revealed that TGM2 was associated with chemoresistance to cisplatin in osteosarcoma cells

Full Text available with Trip Pro

2018 International journal of molecular medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>